Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2017

  • ID: 4337662
  • Report
  • 39 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Domain Therapeutics SA
  • Prexton Therapeutics SA
  • MORE
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2017

Summary:

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. It is a G-protein coupled receptor for glutamate. Glutamate binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Parkinson's Disease, Anxiety Disorders, Autism, Depression, Drug Addiction, Infantile Spasm (West Syndrome), Multiple Sclerosis, Obsessive-Compulsive Disorder, Psychosis, Status Epilepticus and Substance (Drug) Abuse.

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
  • The report reviews Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Domain Therapeutics SA
  • Prexton Therapeutics SA
  • MORE
Introduction

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Overview

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Domain Therapeutics SA

Prexton Therapeutics SA

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Drug Profiles

ADX-88178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JBPOS-0101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXT-2331 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GLUR4 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize mGluR4 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0418506 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Dormant Products

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Product Development Milestones

Featured News & Press Releases

Jul 10, 2017: Parkinson's disease: Prexton announces initiation of phase II clinical testing

Oct 11, 2016: Addex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction

Sep 19, 2016: Parkinsons disease: Prexton Therapeutics completes phase 1 clinical trial

Jun 13, 2016: Addex mGluR4 Program Demonstrates Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases

Mar 07, 2016: Parkinsons disease: Prexton Therapeutics starts phase 1 clinical trial

Dec 09, 2015: Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis

Nov 23, 2015: Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR4 Allosteric Modulator for Neurodegenerative and Psychiatric Diseases

Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases

Sep 24, 2012: Addex Therapeutics's mGluR4 Allosteric Modulator Found To Be Effective In Multiple Sclerosis Model

Jul 16, 2012: Addex Announces Publication Of Positive Data On Efficacy Of New Drug To Treat Parkinson’s Disease In Journal Of Pharmacology And Experimental Therapeutics

Jul 10, 2009: Addex In Collaboration With Merck & Co., Inc. Achieves Second Milestone In Parkinson´s Disease

Feb 25, 2008: Addex In Collaboration With Merck & Co., Inc. Achieves First Milestone In Parkinson’s Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indication, H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Number of Products under Investigation by Universities/Institutes, H2

Products under Investigation by Universities/Institutes, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by Addex Therapeutics Ltd, H2

Pipeline by Domain Therapeutics SA, H2

Pipeline by Prexton Therapeutics SA, H2

Dormant Projects, H2

List of Figures:

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Top 10 Indications, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administrations, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Addex Therapeutics Ltd
  • Domain Therapeutics SA
  • Prexton Therapeutics SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll